All In Biotech

Drug Trial Radar · NCT03004248

Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines

An Open-Label, Multi-Center Trial to Assess the Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines (SAKURA OPEN-LABEL SAFETY)

Last checked: Nov 20, 2026Latest source record: Jul 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,691

Actual

Start

Dec 9, 2016

Primary completion

Oct 17, 2018

Study completion Oct 17, 2018

Sponsor

Lead sponsor
Revance Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Dec 28, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a long term safety study of DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines following single and repeat administration.

Conditions

  • Glabellar Frown Lines

Interventions

  • Botulinum Toxins, Type ABiological

    Intramuscular Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment Emergent Adverse Events (TEAE)Time frame: 0-36 weeks

Locations

61 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Beverly Hills, California

  • Site not named

    Encinitas, California

  • Site not named

    Fremont, California

  • Site not named

    Los Angeles, California

  • Site not named

    Manhattan Beach, California

  • Site not named

    Newport Beach, California

  • Site not named

    Roseville, California

  • Site not named

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    San Diego, California

  • Site not named

    San Francisco, California

  • Site not named

    Santa Monica, California

  • Site not named

    Greenwood Village, Colorado

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Boca Raton, Florida

  • Site not named

    Bradenton, Florida

  • Site not named

    Coral Gables, Florida

  • Site not named

    Miami, Florida

  • Site not named

    West Palm Beach, Florida

  • Site not named

    Chicago, Illinois

  • Site not named

    Lincolnshire, Illinois

  • Site not named

    Naperville, Illinois

  • Site not named

    New Orleans, Louisiana

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Glenn Dale, Maryland

  • Site not named

    Hunt Valley, Maryland

  • Site not named

    Rockville, Maryland

  • Site not named

    Chestnut Hill, Massachusetts

  • Site not named

    Birmingham, Michigan

  • Site not named

    Fridley, Minnesota

  • Site not named

    St Louis, Missouri

  • Site not named

    Omaha, Nebraska

  • Site not named

    Montclair, New Jersey

  • Site not named

    New York, New York

  • Site not named

    New York, New York

  • Site not named

    New York, New York

  • Site not named

    New York, New York

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.